CN1219128A - 增加一氧化氮合成的方法 - Google Patents

增加一氧化氮合成的方法 Download PDF

Info

Publication number
CN1219128A
CN1219128A CN97194727A CN97194727A CN1219128A CN 1219128 A CN1219128 A CN 1219128A CN 97194727 A CN97194727 A CN 97194727A CN 97194727 A CN97194727 A CN 97194727A CN 1219128 A CN1219128 A CN 1219128A
Authority
CN
China
Prior art keywords
phenyl
formula
alkyl
nitric oxide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97194727A
Other languages
English (en)
Chinese (zh)
Inventor
J·P·辛格
D·L·乌德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1219128A publication Critical patent/CN1219128A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
CN97194727A 1996-05-21 1997-05-16 增加一氧化氮合成的方法 Pending CN1219128A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1807196P 1996-05-21 1996-05-21
US60/018,071 1996-05-21

Publications (1)

Publication Number Publication Date
CN1219128A true CN1219128A (zh) 1999-06-09

Family

ID=21786089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194727A Pending CN1219128A (zh) 1996-05-21 1997-05-16 增加一氧化氮合成的方法

Country Status (14)

Country Link
US (1) US5811437A (2)
EP (1) EP0954306A1 (2)
JP (1) JP2000512272A (2)
KR (1) KR20000015805A (2)
CN (1) CN1219128A (2)
AU (1) AU716064B2 (2)
CA (1) CA2255792A1 (2)
EA (1) EA001911B1 (2)
IL (1) IL127152A0 (2)
NO (1) NO985357L (2)
NZ (1) NZ332841A (2)
PL (1) PL330146A1 (2)
WO (1) WO1997044029A1 (2)
YU (1) YU52498A (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010101931A (ko) * 1999-02-03 2001-11-15 피터 지. 스트링거 α1-아드레날린성 수용체 길항제
EP1296674A2 (en) * 2000-07-06 2003-04-02 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
EP1440389A2 (en) 2001-11-02 2004-07-28 Siemens Medical Solutions USA, Inc. Patient data mining for automated compliance
US7457731B2 (en) * 2001-12-14 2008-11-25 Siemens Medical Solutions Usa, Inc. Early detection of disease outbreak using electronic patient data to reduce public health threat from bio-terrorism
US7680086B2 (en) 2002-09-09 2010-03-16 Siemens Canada Limited Wireless local area network with clients having extended freedom of movement
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
US20080275731A1 (en) * 2005-05-18 2008-11-06 Rao R Bharat Patient data mining improvements
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
SE1350212A1 (sv) * 2010-07-21 2013-04-22 Oleg Iliich Epshtein Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US10857983B2 (en) 2017-12-13 2020-12-08 Kyle R. Gillin Leveraged trailer lift

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE69127756T2 (de) * 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
RU2127592C1 (ru) * 1993-12-21 1999-03-20 Эли Лилли Энд Компани Средство для ингибирования окисления липидов низкой плотности и подавления атеросклероза
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration

Also Published As

Publication number Publication date
EP0954306A1 (en) 1999-11-10
WO1997044029A1 (en) 1997-11-27
NZ332841A (en) 2000-06-23
EP0954306A4 (2) 1999-11-10
JP2000512272A (ja) 2000-09-19
KR20000015805A (ko) 2000-03-15
PL330146A1 (en) 1999-04-26
YU52498A (sh) 2000-12-28
EA199801023A1 (ru) 1999-06-24
NO985357D0 (no) 1998-11-17
IL127152A0 (en) 1999-09-22
EA001911B1 (ru) 2001-10-22
AU3134497A (en) 1997-12-09
NO985357L (no) 1998-11-17
US5811437A (en) 1998-09-22
CA2255792A1 (en) 1997-11-27
AU716064B2 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
RU2128992C1 (ru) Средство для ингибирования нейротоксичности, вызываемой бета-амилоидными пептидами
KR19980702079A (ko) 세포-세포 접착의 억제 방법
EP1095654B1 (en) Use of raloxifene and its analogs for the manufacture of a medicament for the Inhibition of LDL oxidation and atherosclerosis
AU716064B2 (en) Methods of increasing nitric oxide synthesis
US6489355B2 (en) Methods of inhibiting the effects of amyloidogenic proteins
CN1165650A (zh) 使用1，1，2-三苯基丁-1-烯衍生物治疗阿尔茨海默病
EA001003B1 (ru) Способ ингибирования ингибитора 1 активатора плазминогена
CN1305342A (zh) 降低高半胱氨酸和c－反应蛋白水平的方法
AU693127B2 (en) Methods of increasing macrophage function
CN1756540A (zh) 非免疫抑制剂2－哌啶酸衍生物在诱导软骨形成分化中的用途
MXPA98009706A (es) Metodos para incrementar la sintesis de oxido nitrico
HK1082415A (en) Treatment of gastrointestinal disorders with duloxetine
MXPA97006424A (en) Use of moxonidine for the treatment of the aterosclero

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication